Adaptive Biotechnologies Corp (ADPT)vsNatera Inc (NTRA)
ADPT
Adaptive Biotechnologies Corp
$24.20
-0.12%
HEALTHCARE · Cap: $3.90B
NTRA
Natera Inc
$328.93
+0.86%
HEALTHCARE · Cap: $46.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 779% more annual revenue ($2.71B vs $308.08M). NTRA leads profitability with a -7.1% profit margin vs -20.7%. NTRA earns a higher WallStSmart Score of 31/100 (F).
ADPT
Avoid28
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.0%
Fair Value
$31.91
Current Price
$24.20
$7.71 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Trading at 26.9x book value
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
0.0% earnings growth
Weak financial health signals
Trading at 25.9x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : ADPT
The primary concerns for ADPT are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ADPT profiles as a growth stock while NTRA is a hypergrowth play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.10 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
ADPT generates stronger free cash flow (-8M), providing more financial flexibility.
Bottom Line
NTRA scores higher overall (31/100 vs 28/100) and 37.7% revenue growth. ADPT offers better value entry with a 51.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?